Bioscrip Inc (BIOS) 2.58 $BIOS Healthcare Sector

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Bioscrip Inc (BIOS) 2.58 $BIOS

Healthcare Sector Equities Under Review -- Intrexon, Alkermes, BioScrip, and Heartware Intl.
PR Newswire - Tue Jul 26, 7:50AM CDT
The Healthcare sector presents some of the most profitable trades in the market, but challenges, such as ransom-ware risks, demand pressures, and cost issues, continue to persist. Today, Stock-Callers.com presents these four companies for further assessment: Intrexon Corp. (NYSE: XON), Alkermes PLC (NASDAQ: ALKS), BioScrip Inc. (NASDAQ: BIOS), and Heartware International Inc. (NASDAQ: HTWR). Learn more about these stocks by accessing their freenotes at:
XON: 27.38 (+2.05), BIOS: 2.58 (+0.02), HTWR: 57.96 (+0.02), ALKS: 49.56 (-0.34)

BioScrip To Host 2016 Second Quarter Results Call
GlobeNewswire - Tue Jul 26, 2:28AM CDT
BioScrip, Inc. (NASDAQ:BIOS) announced today that the Company will release its 2016 second quarter financial results on Monday, August 8, 2016, before the opening of the U.S. financial markets.
BIOS: 2.58 (+0.02)

Quest Diagnostics: Strong Q2, Strategic Initiatives Add Value
Zacks Equity Research - Zacks Investment Research - Mon Jul 25, 2:23PM CDT
On Jul 22, 2016, we issued an updated research report on Quest Diagnostics, Inc. (DGX).
AMSG: 72.23 (-2.78), HCA: 75.52 (-1.61), LHCG: 45.32 (+0.06), DGX: 86.24 (-0.12), BIOS: 2.58 (+0.02)

3 Reasons Growth Stock Investors Will Love BioScrip (BIOS)
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 7:34AM CDT
BioScrip, Inc. (BIOS) is one such company that stands out in terms of value scorecard.
BIOS: 2.58 (+0.02)

Quest Diagnostics Estimates Move Up, Tie-Ups to Add Value
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 7:31AM CDT
On Jul 11, we issued an updated research report on Quest Diagnostics, Inc. (DGX).
AMSG: 72.23 (-2.78), HCA: 75.52 (-1.61), DGX: 86.24 (-0.12), BIOS: 2.58 (+0.02)

BioScrip Completes Public Offering of Common Stock
GlobeNewswire - Wed Jun 22, 9:13AM CDT
BioScrip, Inc. (NASDAQ:BIOS) (the "Company" or "BioScrip" announced today that it has completed its previously announced underwritten public offering (the "Offering" of 45,200,000 shares of its common stock, including 5,200,000 shares of common stock issued upon full exercise of the underwriters' over-allotment option, at a public offering price of $2.00 per share. The Offering resulted in net proceeds of approximately $83.15 million, after deducting underwriting discounts and commissions and offering expenses. Jefferies LLC acted as the lead joint book-running manager, SunTrust Robinson Humphrey, Inc. acted as a passive book-running manager and Craig-Hallum Capital Group LLC acted as a co-manager.
BIOS: 2.58 (+0.02)

BioScrip Prices Underwritten Offering of Common Stock
GlobeNewswire - Thu Jun 16, 9:20PM CDT
BioScrip, Inc. (NASDAQ:BIOS) (the "Company" or "BioScrip" today announced the pricing of an underwritten offering of 40,000,000 shares of its common stock (the "Offering" at a price to the public of $2.00 per share (the "Offering Price". Jefferies LLC is acting as the lead joint book-running manager and SunTrust Robinson Humphrey, Inc. is acting as a passive book-running manager. Craig-Hallum Capital Group LLC is acting as a co-manager. The Company has granted the underwriters an option for a period of 30 days to purchase up to an additional 5,200,000 shares of the Company's common stock at the Offering Price. The Company expects to receive approximately $73.38 million in net proceeds from the offering after deducting underwriting discounts and commissions and other offering expenses payable by the Company, assuming no exercise by the underwriters of their option to purchase additional shares, or approximately $83.15 million if the underwriters exercise their option to purchase additional shares in full.
BIOS: 2.58 (+0.02)

BioScrip (BIOS): Soft Revenue Outlook & Weak Margins Linger
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 7:18AM CDT
On Jun 13, 2016, we issued an updated research report on BioScrip, Inc. (BIOS).
USPH: 58.87 (-0.75), LHCG: 45.32 (+0.06), BIOS: 2.58 (+0.02), HLS: 42.05 (-1.00)

BioScrip (BIOS) in Focus: Stock Adds 8.4% in Session
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 7:00AM CDT
BioScrip , Inc. (BIOS) was a big mover last session, as the company's shares rose over 8% on the day.
LHCG: 45.32 (+0.06), BIOS: 2.58 (+0.02)

BioScrip (BIOS) Q1 Loss Wider than Expected, Revenues Beat
Zacks Equity Research - Zacks Investment Research - Tue May 10, 8:11AM CDT
BioScrip, Inc. (BIOS) reported net loss from continuing operations of 17 cents per share in the first quarter of 2016.
USPH: 58.87 (-0.75), AFAM: 40.05 (+0.26), BIOS: 2.58 (+0.02), HLS: 42.05 (-1.00)

BioScrip Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 3:30PM CDT
BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company" today announced financial results for the first quarter 2016. For the first quarter, the Company reported revenue from continuing operations of $238.5 million, net loss from continuing operations of ($11.9) million and diluted EPS of ($0.17) loss per share.
BIOS: 2.58 (+0.02)

BioScrip To Host 2016 First Quarter Results Call
GlobeNewswire - Mon Apr 18, 3:30PM CDT
BioScrip, Inc. (NASDAQ:BIOS) announced today that the Company will release its 2015 first quarter financial results on Thursday, May 5, 2016, after the close of the U.S. financial markets.
BIOS: 2.58 (+0.02)

BioScrip Announces Filing of Shelf Registration Statement to Replace Expiring Registration Statement
GlobeNewswire - Fri Apr 01, 11:06AM CDT
BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company" today announced that, in order to replace its expiring registration statement, it has filed to renew its current shelf registration statement on Form S-3 with the U.S. Securities and Exchange Commission (SEC). The registration statement is subject to review by the SEC.
BIOS: 2.58 (+0.02)

Bernstein Litowitz Berger & Grossmann LLP Announces Proposed Settlement of In Re BioScrip, Inc. Securities Litigation
PR Newswire - Thu Mar 24, 9:00AM CDT
UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK
BIOS: 2.58 (+0.02)

BioScrip Soars on Progress in Financial Improvement Plan
Zacks Equity Research - Zacks Investment Research - Thu Jan 21, 12:40PM CST
BioScrip (BIOS) also successfully implemented its cost reduction programs, which are expected to reduce infusion field related costs by $5 million in 2016.
CAPR: 3.58 (-0.12), ABAX: 49.14 (-0.32), LMAT: 17.89 (+0.69), BIOS: 2.58 (+0.02)

BioScrip Provides Business Update on Implementation of Financial Improvement Plan and Progress to Enhance Shareholder Value
GlobeNewswire - Tue Jan 19, 5:50AM CST
Review of Strategic Alternatives Continues
BIOS: 2.58 (+0.02)

BioScrip: Infusion Services Offers Hope amid Margin Woes
Zacks Equity Research - Zacks Investment Research - Tue Dec 22, 1:50PM CST
On Dec 21, we issued an updated research report on BioScrip, Inc. (BIOS) ??? provider of home infusion and pharmacy benefit management (PBM) services.
ICUI: 117.07 (+0.31), INSY: 15.91 (+0.26), ABAX: 49.14 (-0.32), BIOS: 2.58 (+0.02)

Where Investors Are Going - New Reports on II-VI Inc., Performance Sports Group, BioScrip and Rapid7
ACCESSWIRE - Mon Dec 14, 6:50AM CST
NEW YORK, NY / ACCESSWIRE / December 14, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: II-VI Inc. (NASDAQ: IVII), Performance Sports Group Ltd (NYSE: PSG), BioScrip Inc. (NASDAQ: BIOS) and Rapid7 Inc. (NASDAQ: RPD). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
PSG: 3.32 (-0.01), RPD: 14.01 (+0.03), BIOS: 2.58 (+0.02), IIVI: 20.37 (+0.27)

Trading Ahead of Upcoming Developments - Research on Vivus, ReneSola, Consumer Portfolio Services and BioScrip
ACCESSWIRE - Mon Nov 23, 7:20AM CST
NEW YORK, NY / ACCESSWIRE / November 23, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Vivus Inc. (NASDAQ: VVUS), ReneSola Ltd. (NYSE: SOL), Consumer Portfolio Services Inc. (NASDAQ: CPSS) and BioScrip Inc. (NASDAQ: BIOS). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
SOL: 1.25 (+0.05), CPSS: 4.58 (+0.34), VVUS: 1.05 (-0.02), BIOS: 2.58 (+0.02)

BioScrip's Strategic Plans on Track, Margin Concerns Stay
Zacks Equity Research - Zacks Investment Research - Tue Nov 17, 1:30PM CST
On Nov 13, we issued an updated research report on Bioscrip, Inc. (BIOS) ??? provider of home infusion and pharmacy benefit management (PBM) services.
ICUI: 117.07 (+0.31), NXTM: 22.09 (-0.02), BIOS: 2.58 (+0.02), HRC: 54.02 (+0.59)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s Second IND Adds Proof to Its Glue Platform

Updated Category News Views 25

Two IND acceptances from one long-running alliance is not nothing, especially in a drug-discovery business where plenty of polished platform talk never makes it to the clinic. Evotec has cleared that modest but meaningful bar again with Bristol Myers Squibb: a second molecular-glue candidate has received FDA acceptance for an Investigational New Drug application. The...

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 125

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading
Miami I20 Tests Appetite for Long-Term U.S. Capital

Updated Category News Views 154

Five days in a Miami airport hotel may not sound like the machinery of national investment policy, yet the guest list for the inaugural I20 Summit is serious enough to make capital markets sit up. From December 11 through 15, the Sovereign Wealth Fund Institute plans to bring sovereign funds, pensions, endowments, family offices, business leaders and U.S....

Continue Reading
WeWalk Brings Diabetes Support Back to Dubai Science Park

Updated Category News Views 32

Before sunrise on 21 November, a 3.5 km route in Dubai Science Park will carry a purpose bigger than sneakers and weekend fitness. WeWalk is returning for its seventh edition, with TECOM Group PJSC and Dubai Charity Association again putting the event behind support for children living with diabetes. That deserves to be said plainly: this is a community health effort, not...

Continue Reading
Weatherford Adds Grant Roach to Its Sports Deal Team

Updated Category News Views 69

Sports investing has reached that awkward middle age where everybody sees the runway, but few can explain exactly where the bumps are. Weatherford Capital’s decision to bring Grant Roach aboard as vice president is not a headline packed with transaction fireworks. It is, however, a pretty clear tell: the Tampa firm intends to put more bodies and more underwriting muscle...

Continue Reading
Travelzoo Turns Thanksgiving Delays Into Member Value

Updated Category News Views 108

Airport gridlock is a miserable place to make a membership pitch, yet Travelzoo has found a pretty shrewd angle for it. On November 18, the company said nearly 20 million travelers will move through airports during the upcoming Thanksgiving holiday, when cancellations and delays can turn an ordinary trip into a long, fluorescent-lit slog. Its offer: qualifying Club...

Continue Reading
Layne’s Jacksonville Debut Tests East Texas Expansion

Updated Category News Views 57

Jacksonville is not some flashy coastal launch, and that is precisely why this Layne’s Chicken Fingers opening matters. A new chicken tender shop at 1217 S. Jackson St. will not move public markets, because this is a franchise-growth story rather than a ticker story. But it does offer a clean look at whether Layne’s can turn its Texas roots into a durable multi-market...

Continue Reading
Adecco Finds AI Value Depends on Better Work Redesign

Updated Category News Views 39

A shiny AI license is not a productivity strategy, and Adecco's latest workforce survey puts some hard numbers behind that irritation. The company surveyed 40,500 workers in 36 countries for its seventh Global Workforce of the Future report, released November 19, 2026. Its central finding is disarmingly sensible: AI produces more when companies rebuild the work around it...

Continue Reading
CHN Energy's Indonesia Record Deserves a Hard Look

Updated Category News Views 50

Twenty years of boots sinking into swamp mud tells a sturdier story than a polished anniversary slogan. CHN Energy says it entered Indonesia's energy market two decades ago and has since built an operating presence around reliable electricity, local training and community work. In a country scattered across thousands of islands, dependable power is not some decorative...

Continue Reading
Vector's Peptide Pact Needs Proof Before Any Payday

Updated Category News Views 194

A famous orthopedic name can open doors, but it cannot manufacture clinical evidence. That is the plain reality behind Vector Science and Therapeutics' new collaboration with the Andrews Research & Education Foundation. Dr. James Andrews carries enormous credibility in sports medicine, earned across more than five decades of work. For Vector, that association matters. For...

Continue Reading

Top 5 Most Recently Viewed Articles

Appian Partners with Children's National to Elevate Healthcare

Updated Category News Views 87

Appian Teams Up with Children’s National Hospital Appian, known for its cutting-edge software solutions, is excited to share its new collaboration with Children’s National Hospital, one of the top names in pediatric healthcare. This partnership aims to raise awareness and gather essential resources for children's health. Appian is dedicated to enhancing the healthcare...

Continue Reading
Deutsche Bank Predicts ECB Rate Cuts Amid Falling Inflation

Updated Category News Views 101

Deutsche Bank dropped a prediction back in late 2023 that the European Central Bank (ECB) was gearing up for interest rate cuts this October. Traders perked up when they caught wind of unexpected dips in inflation figures from the eurozone noted earlier that September. Why the Cut? Inflation Insights Unpacked Analysts at Deutsche Bank, led by chief economist Mark Wall,...

Continue Reading
Vipshop's Financial Performance Analysis for 2024 Revealed

Updated Category News Views 390

Vipshop's Financial Insights for 2024 Vipshop Holdings Limited (NYSE: VIPS), a prominent online discount retailer in the Chinese market, has recently shared its unaudited financial results for the quarter and full year that concluded on December 31, 2024. Despite encountering challenges over the previous year, Vipshop's performance indicates resilience and potential...

Continue Reading
Boston University and Infocap Partner for Digital Transformation

Updated Category News Views 207

Boston University's Digital Business Institute Partners with Infocap BOSTON--The Digital Business Institute (DBI) at Boston University Questrom School of Business and Infocap AI Corp, a leader in human-centric automation, have announced a strategic partnership aimed at revolutionizing digital transformation across the banking sector. This collaboration is particularly...

Continue Reading
Disclosure and Investment Position Overview for Keywords Studios

Updated Category News Views 116

Understanding Disclosure and Investment Positions In the complex world of stock market investments, transparency is crucial. This is especially true for organizations involved with Keywords Studios PLC, a leading player in the gaming services sector. This article seeks to shed light on the recent disclosures and key investments associated with this prominent company. Key...

Continue Reading